Cimzia: new TNF-alpha inhibitor

Cimzia is a new addition to the management of moderate to severely active rheumatoid arthritis in combination with methotrexate or as monotherapy.


Certolizumab pegol is a PEGylated formulation of a humanized monoclonal antibody specific for tnf-α.


In two studies comparing the use of certolizumab and MTX to placebo and MTX, significantly more patients in the certolizumab groups achieved the American College of Rheumatology 20 per cent criteria for improvement (ACR20) at 24 weeks.1,2

The most common adverse effects in the trials were headache, hypertension, UTI, URTI and back pain.1,2

View Cimzia drug record


  1. Keystone E et al. Arthritis Rheumatism 2008; 58:3319-29.
  2. Smolen J et al. Ann Rheum Dis 2009; 68:797-804.

Further information: UCB

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more